Revlimid — CareFirst (Caremark)
Myelofibrosis-associated anemia
Initial criteria
- Medication given as single agent or with prednisone AND serum erythropoietin (EPO) ≥ 500 mU/mL OR EPO < 500 mU/mL with no response or loss of response to erythropoiesis-stimulating agents.
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months